Patents by Inventor Kenneth Emancipator

Kenneth Emancipator has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SCORING METHODS FOR ANTI-PD THERAPY ELIGIBILITY AND COMPOSITIONS FOR PERFORMING SAME
    Publication number: 20230152326
    Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.
    Type: Application
    Filed: January 18, 2023
    Publication date: May 18, 2023
    Inventors: Karina Kulangara, Nancy Zhang, David Stanforth, Greg Angelides, Stephanie Waldroup, Kenneth Emancipator
  • Scoring methods for anti-PD therapy eligibility and compositions for performing same
    Patent number: 11585817
    Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: February 21, 2023
    Assignees: AGILENT TECHNOLOGIES, INC., MERCK SHARP & DOHME LLC
    Inventors: Karina Kulangara, Nancy Zhang, David Stanforth, Greg Angelides, Stephanie Waldroup, Kenneth Emancipator
  • Immunohistochemical assay for detecting expression of programmed death ligand 1 (PD-L1) in tumor tissue
    Patent number: 11193937
    Abstract: The present disclosure provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections as detected by immunohistochemical assay using an antibody that specifically binds to PD-L1. The results generated using these processes have a variety of experimental, diagnostic and prognostic applications.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: December 7, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Marisa Dolled-Filhart, Kenneth Emancipator, Frank Lynch, Robert H. Pierce, Dianna Wu
  • DOSING REGIMEN OF ANTI-LAG3 ANTIBODY AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODY FOR TREATING CANCER
    Publication number: 20210347889
    Abstract: The present invention relates to dosing regimens of an anti-LAG3 antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an antibody of Lymphocyte-Activation Gene 3 (LAG3). The invention also provides a method for treating cancer in a patient comprising administering to the patient an anti-LAG3 antibody and an anti-PD-1 antibody, wherein the tumor tissue section of the patient is PD-L 1 expression positive, and optionally LAG3 expression positive.
    Type: Application
    Filed: November 4, 2019
    Publication date: November 11, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anson Kunjachan Abraham, Elliot K. Chartash, Kenneth Emancipator, Rosario Garrido, Jane Anne Healy, Jonathan W. Juco, Diane Levitan, Qing Zhao
  • SCORING METHODS FOR ANTI-PD THERAPY ELIGIBILITY AND COMPOSITIONS FOR PERFORMING SAME
    Publication number: 20200200759
    Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.
    Type: Application
    Filed: February 28, 2020
    Publication date: June 25, 2020
    Inventors: Karina Kulangara, Nancy Zhang, David Stanforth, Greg Angelides, Stephanie Waldroup, Kenneth Emancipator
  • Scoring methods for anti-PD therapy eligibility and compositions for performing same
    Patent number: 10613092
    Abstract: Aspects of the present disclosure provide methods for determining the eligibility of a subject having a malignancy for treatment with an anti-PD therapeutic agent based on a Combined Positive Score (CPS) for a tumor tissue sample from the subject. Compositions and kits or performing the disclosed methods are also provided.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: April 7, 2020
    Assignees: Agilent Technologies, Inc., Merck Sharp & Dohme Corp.
    Inventors: Karina Kulangara, Nancy Zhang, David Stanforth, Greg Angelides, Stephanie Waldroup, Kenneth Emancipator
  • IMMUNOHISTOCHEMICAL ASSAY FOR DETECTING EXPRESSION OF PROGRAMMED DEATH LIGAND 1 (PD-L1) IN TUMOR TISSUE
    Publication number: 20180080938
    Abstract: The present disclosure provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections as detected by immunohistochemical assay using an antibody that specifically binds to PD-L1. The results generated using these processes have a variety of experimental, diagnostic and prognostic applications.
    Type: Application
    Filed: September 22, 2017
    Publication date: March 22, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Marisa Dolled-Filhart, Kenneth Emancipator, Frank Lynch, Robert H. Pierce, Dianna Wu
  • IMMUNOHISTOCHEMICAL ASSAY FOR DETECTING EXPRESSION OF PROGRAMMED DEATH LIGAND 1 (PD-L1) IN TUMOR TISSUE
    Publication number: 20160084839
    Abstract: The present disclosure provides processes for describing and quantifying the expression of human programmed death ligand-1 (PD-L1) in tumor tissue sections as detected by immunohistochemical assay using an antibody that specifically binds to PD-L1. The results generated using these processes have a variety of experimental, diagnostic and prognostic applications.
    Type: Application
    Filed: March 31, 2014
    Publication date: March 24, 2016
    Inventors: Marisa Dolled-Filhart, Kenneth Emancipator, JR., Frank Lynch, Robert H. Pierce, Dianna Wu